Pharma & Biotech - Page 14

The global pharmaceutical cold chain market faces mounting pressure as high-value, temperature-sensitive medications become an increasingly significant share of drug pipelines worldwide. Biologics, vaccines, and cell and gene therapies require strict temperature

A federal appeals court has overturned the 2024 dismissal of a lawsuit accusing Bristol Myers Squibb of deliberately delaying approval of blood cancer drug Breyanzi. The U.S. Circuit Court of Appeals in

Pharmaceutical companies across the United States are facing mounting pressure from three distinct tariff tracks that are reshaping how the industry plans its domestic manufacturing footprint. The second episode of the Supply

Regeneron Genetics Center has spent 14 years building one of the most formidable genomic research operations in the pharmaceutical industry today. The center, known as RGC, serves as the genomic research branch

Novo Nordisk CEO Mike Doustdar is challenging the widely held investor view that the booming obesity drug market can only produce one clear winner. Speaking to Reuters in an interview published Thursday,

The pharmaceutical cold-chain logistics sector is undergoing significant transformation as industry expectations around product integrity continue to rise sharply. Maintaining precise temperature control throughout the supply chain has become one of the

Karyopharm Therapeutics is confronting a critical financial deadline, with a debt payment due in four weeks and cash reserves barely sufficient to survive into September. The Massachusetts-based biopharma reported its second quarter

AstraZeneca’s (AZN) first-in-class hypertension drug Baxfendy does not meet cost-effectiveness standards relative to its price, according to U.S. drug price watchdog ICER. The Institute for Clinical and Economic Review published a draft

Amy Niles, chief mission officer at the Patient Advocate Foundation, formerly known as the PAN Foundation, has outlined her vision for patient access reform in 2026. Niles warns that while several healthcare

Abbott (NYSE: ABT) and the Big Ten Conference are relaunching their “We Give Blood” campaign as the United States grapples with a severe national blood shortage. The American Red Cross has declared